Crescent Biopharma (CBIO) Gains from Investment Securities (2016 - 2026)

Crescent Biopharma (CBIO) has 11 years of Gains from Investment Securities data on file, last reported at $5000.0 in Q1 2026.

• Gains from Investment Securities for Q1 2026 came in at $5000.0, changed N/A year-over-year; the trailing twelve-month figure through Mar 2026 was $1.7 million (up 1958.47% YoY), and the FY2025 annual result was $1.7 million, down 86.34% from the prior year.
• Gains from Investment Securities fell to $5000.0 in Q1 2026 per CBIO's latest filing, from $51000.0 in the prior quarter.
• Over five years, Gains from Investment Securities peaked at $8.8 million in Q2 2023 and troughed at -$90720.0 in Q4 2023.
• A 5-year average of $1.7 million and a median of $584200.0 in 2022 frame the typical range for Gains from Investment Securities.
• The sharpest annual moves came in 2022 and 2024: Gains from Investment Securities slumped 97.9% in 2022, then surged 2415.33% in 2024.
• A 5-year view of Gains from Investment Securities shows it stood at $584200.0 in 2022, then plunged by 115.53% to -$90720.0 in 2023, then soared by 743.96% to $584200.0 in 2024, then tumbled by 91.27% to $51000.0 in 2025, then sank by 90.2% to $5000.0 in 2026.
• Business Quant data shows CBIO's Gains from Investment Securities at $5000.0 in Q1 2026, $51000.0 in Q3 2025, and $1.6 million in Q2 2025.